Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Investment analysts at HC Wainwright decreased their Q2 2023 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Thursday, May 11th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.15) per share for the quarter, […]